Figure 6. M002 treatment of malignant rhabdoid kidney tumor xenografts.

G401 human MRKT cells (2.5×10⁶ cells) in Matrigel™ were injected into the right flank of female athymic nude mice. Once tumors reached 250 mm³, animals received an intra-tumoral injection of vehicle [PBS +10% glycerol, 50 µL (n = 5)] or M002 virus [1×10⁷ PFU/50 µL (n = 10)]. Following injection, the vehicle treated and half of the M002 treated animals were given 3Gy irradiation to the tumor. A Kaplan-Meier graph for animal survival. Animals treated with M002 alone or with M002+ XRT had a significant increase in survival over those treated with vehicle+XRT. There was no significant survival advantage seen with the addition of XRT to the M002 treatment. B Tumor volumes were measured twice weekly [(width)²×length]/2. Data reported as mean fold change in tumor volume ± standard error. In the M002 treated G401 xenografts, there was a significant decrease in tumor growth that began at day 7 following treatment that continued to the end of the study. The addition of low dose XRT to M002 treatments had no significant effect upon tumor growth.